TABLE 3.
Clinical data according to HDL-C levels.
| Low HDL-C group (n = 21) | High HDL-C group (n = 179) | P | |
| Male [n (%)] | 18 (85.7) | 156 (87.2) | 1.000 |
| Age (years) | 57.00 ± 13.40 | 47.22 ± 11.07 | <0.001 |
| Expense (USD) | 9479.7 (5448.1–17680.8) | 11238.2 (6761.9–17756.1) | 0.482 |
| WBC (109/L) | 6.67 (5.25–8.53) | 5.53 (4.40–7.50) | 0.045 |
| PLT (109/L) | 81.00 (48.00–121.50) | 114.00 (82.00–144.00) | 0.012 |
| INR | 2.12 (1.64–2.68) | 1.94 (1.71–2.52) | 0.634 |
| PT (s) | 23.60 (18.45–28.45) | 21.80 (19.20–27.85) | 0.785 |
| Hb (g/L) | 126.00 (108.00–139.00) | 123.00 (110.00–138.00) | 0.757 |
| Albumin (g/L) | 30.92 ± 2.78 | 31.53 ± 4.68 | 0.558 |
| Creatinine (μmol/L) | 74.20 (60.80–97.05) | 64.90 (57.20–79.80) | 0.110 |
| BUN (mmol/L) | 5.40 (3.60–8.35) | 4.00 (2.60–5.45) | 0.007 |
| ALT (μ/L) | 383.00 (126.00–947.00) | 253.00 (111.35–625.35) | 0.291 |
| AST (μ/L) | 198.00 (142.50–351.25) | 249.00 (131.40–629.00) | 0.511 |
| Bilirubin (μmol/L) | 382.77 ± 137.96 | 308.05 ± 133.68 | 0.017 |
| TC (mg/dL) | 85.43 (68.23–102.06) | 100.90 (78.48–121.01) | 0.018 |
| CTPs | 12.00 (10.50–12.00) | 11.00 (10.00–12.00) | 0.046 |
| MELDs | 25.04 (22.01–28.72) | 22.21 (19.55–26.23) | 0.021 |
| COSSH-ACLF IIs | 7.63 (7.08–8.64) | 6.88 (6.36–7.69) | 0.001 |
| 28-days mortality [n (%)] | 18 (85.71) | 36 (20.11) | <0.001 |
P-value < 0.05 was considered significant and was indicated in bold. ACLF, acute on chronic liver failure; HBV, hepatitis B Virus; USD, dollar; WBC, white blood cell count; PLT, platelet; INR, international normalized ratio; PT, prothrombin time; Hb, hemoglobin; BUN, blood urea nitrogen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; CTPs, child-turcotte-pugh score; MELDs, model for end-stage liver disease score; COSSH-ACLF IIs, Chinese Group on the Study of Severe Hepatitis B-ACLF II score.